VRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy VRTX now. The trend is still bullish (stacked moving averages), options positioning is moderately risk-on (puts below calls), and Wall Street sentiment/targets have turned sharply more constructive into multiple 2026 pipeline readouts and the upcoming 2025 Q4 earnings (Feb 12 AH). Despite hedge-fund selling and a slightly soft near-term statistical drift, the current pullback toward the pivot zone looks like a reasonable immediate entry for an impatient investor.
Price/Trend: VRTX closed at 468.56 (-1.22% day), but the broader trend remains bullish with SMA_5 > SMA_20 > SMA_200 (classic uptrend structure). Momentum: MACD histogram is positive (1.31) but contracting, implying upside momentum is slowing rather than reversing. RSI_6 at ~54 is neutral, consistent with consolidation rather than overbought conditions. Levels: Pivot ~459.83 is the key nearby support/decision area; below that, S1 ~438.44. Overhead resistance sits at R1 ~481.22, then R2 ~494.44. From 468.56, the stock is closer to support than the next major resistance, making the pullback buyable for a quick-moving investor. Pattern-based short-term odds: Similar-pattern model suggests mild near-term softness (next day -0.32%, next week -1.81%) but a positive 1-month bias (+1.48%).
Intellectia Proprietary Trading Signals
reinforce a strong pro-2026 setup.
Earnings catalyst: QDEC 2025 earnings on 2026-02-12 after hours (Street EPS est. 4.
can reset expectations and provide a near-term sentiment catalyst.
Positioning/flows: Hedge funds are net selling, with selling amount up 149.17% over the last quarter—this can cap rallies in the near term.
Momentum cooling: MACD is still positive but contracting, implying reduced upside speed and a higher chance of chop/consolidation.
Near-term resistance: Overhead levels at ~481 and ~494 could slow immediate upside if buyers don’t step in decisively.
News feed signal-to-noise: Recent news stream includes non-VRTX items (Avant Technologies), reducing the amount of fresh, company-specific positive headlines beyond general ‘set for growth’ commentary.
Latest reported quarter: 2025/Q3. Growth: Revenue 3.076B (+10.99% YoY) shows solid top-line expansion. Profitability: Net income 1.083B (+3.59% YoY) and EPS 4.2 (+4.74% YoY) indicate earnings growth, though slower than revenue (suggesting higher investment/spend or mix effects). Margins: Gross margin 86.52% (up 0.79% YoY) remains exceptionally strong and slightly improving—supportive of premium biotech quality and funding pipeline execution.
Recent trend: Clear upgrade cycle with rising price targets through Dec 2025–Jan 2026. Notable changes include Barclays upgrade to Overweight with PT 606 (from 414), RBC upgrade to Outperform with PT 546 (from 455), Evercore Outperform with PT 530 (from 475), and UBS maintaining Buy while lifting PT to 545. Wall Street pros: (1) Increasing confidence in kidney/IgAN pipeline as a diversification and growth engine; (2) CF franchise durability and continued cash generation; (3) Multiple upcoming data/readout catalysts that can re-rate the stock. Wall Street cons: (1) Some concern that guidance could be conservative after prior rallies; (2) Execution/data-readout dependency for the renal franchise to justify higher multiples.
